nose deformity
Recently Published Documents


TOTAL DOCUMENTS

210
(FIVE YEARS 37)

H-INDEX

18
(FIVE YEARS 1)

2021 ◽  
Vol 48 (6) ◽  
pp. 630-634
Author(s):  
Hyun Seung Lee ◽  
Hyung Joon Seo ◽  
Yong Chan Bae

To date, there have been no reports of patients showing a Tessier number 7 cleft with unilateral complete cleft lip and palate. Furthermore, no studies have established the sequence, plan, or timing of surgical methods for treating patients presenting the above anomalies simultaneously. We report a case of a Tessier number 7 cleft with unilateral complete cleft lip and palate. Two months after birth, lip adhesion was performed on the unilateral complete cleft lip and total excision was performed on the skin tag. At 4 months of age, Tessier number 7 cleft was corrected. At 6 months of age, surgery involving two small triangular flaps was performed on the unilateral incomplete cleft lip after performing lip adhesion. At 13 months of age, two-flap palatoplasty with a vomer flap was performed on the complete cleft palate. At 6 years of age, open rhinoplasty was performed on the unilateral cleft lip nose deformity. At 9 years of age, bone grafting was performed for the alveolar cleft. At follow-up appointments up to 13 years of age, there were no major complications. Here, we present this patient, surgical procedures and timelines, and show our results demonstrating good postoperative outcomes.


Author(s):  
Robin Jacquot ◽  
Arthur Bert ◽  
François Durupt ◽  
Yvan Jamilloux ◽  
Pascal Seve

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 346-347
Author(s):  
C. Schaap ◽  
R. Krol ◽  
H. H. F. Remmelts ◽  
R. Klaasen ◽  
E. Hagen ◽  
...  

Background:Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) is a necrotizing vasculitis, predominantly affecting small or medium vessels with few or no immune deposits. Ear, nose and throat (ENT) involvement in AAV is frequently present. AAV has a relapsing-remitting disease course. A factor that has been associated with induction of relapses is nasal Staphylococcus aureus (S. aureus) colonization. This alleged association between nasal colonization and induction of relapses has resulted in the use of antibiotics. However, the effect of antibiotic treatment on disease activity remains controversial. Some studies showed a beneficial effect of antibiotic treatment whereas other studies found no effect of antibiotic treatment on disease activity.Objectives:The aim of this study was to identify the role of nasal S. aureus colonization and the effect of systemic or local antibiotic treatment on disease activity in patients with AAV.Methods:Clinical, laboratory and histological data from all AAV patients with ENT involvement, diagnosed in two medical centers between 1981 and 2020, were retrospectively collected. Nasal S. aureus colonization was defined as at least one positive nasal swab during follow-up. Data on systemic (cotrimoxazole and azithromycin) and local antibiotics (mupirocin) use was collected. Disease activity was divided into systemic and local disease activity. Systemic disease activity consisted of history of relapses, relapse number per patient years and Birmingham vasculitis activity score version 3 (BVAS3) at last visit. Local disease activity included history of ENT relapses, development of saddle nose deformity or subglottic stenosis during follow-up.Results:Two-hundred and thirteen patients were included in the analysis. Median follow-up time was 8 (IQR 3 -17) years. S. aureus colonization was tested in 100 (46.9%) cases of which 44 patients tested positive. Only one patient developed a subglottic stenosis, and 13 patients developed a saddle nose deformity during follow-up. Systemic and local disease activity at baseline and at last visit were comparable between patients with and without and S. aureus colonization. Regression analysis showed no difference in relapse number per patient year between AAV patients colonized with S. aureus versus non-colonized patients (RR 2.03; 95%CI, 0.97 – 4.26, p=0.06). This also accounted for local ENT relapses (OR 0.134; 95%CI 0.06-1.47, p=0.14) and saddle nose deformity (OR 0.61; 95%CI 0.04-10.68, p=0.74). Twenty-eight (13.1%) S. aureus positive patients received antibiotics aimed at eradication of S. aureus. Twenty-two (10.3%) received cotrimoxazole, 2 (0.9%) received azithromycin and 17 (8.0%) patients received mupirocin ointment. No significant difference was found between the treated versus non-treated group with regard to systemic and local disease activity.Conclusion:Nasal S. aureus colonization does not influence systemic or local disease activity. Antibiotic eradication treatment did not modify disease activity in this study.Table 1.Effect of AB treatment on disease activity of 40 AAV patients with ENT involvement and S. aureus colonizationDisease activityAntibiotic treatmentP-valueYes (n=28)No (n=12)Systemic symptomsHistory of one or more relapses, n (%)18 (47.4%)4 (10.5%)0.635Relapse number per patient years, median (IQR) *0.11 (0-0.18)0.17 (0.02 – 0.26)0.346BVAS3 last visit, median (IQR)1 (0-4)1 (0-4)0.932Local symptomsHistory of one or more ENT relapses, n(%) *9 (33.3%)3 (11.1%)0.438Development of saddle nose deformity during follow-up, n (%) *4 (12.1%)0 (0%)0.367Values are median (interquartile range IQR) or n (%). BVAS3: Birmingham Vasculitis Activity Score version 3; ANCA: Anti-Neutrophilic Cytoplasmic Autoantibody; AAV: ANCA associated vasculitis; ENT: ear, nose and throat. * More than 10% missings in analysis. For an overview of the number of included patients per analysis, see supplementary table B.Disclosure of Interests:None declared


2020 ◽  
pp. 105566562098022
Author(s):  
Angel D. Pagan ◽  
David A. Sterling ◽  
Brian T. Andrews

Objective: To compare cartilage grafting outcomes in intermediate versus definitive cleft rhinoplasty. Design: A retrospective chart review was conducted. The χ2 and Fisher exact tests were used for statistical analyses. Results were considered statistically significant at P < .05. Participants: All subjects who underwent revision cleft rhinoplasties between July 2011 and June 2019 were included. Subjects with syndromic conditions were excluded. Results: A total of 46 subjects with a cleft nose deformity underwent 65 rhinoplasty procedures. The ages averaged 17 years (range 5-50) with 34 (73.9%) males and 12 (26.1%) females. In the intermediate group, 6 (28.6%) subjects required cartilage grafting as part of 6 cleft rhinoplasties, whereas 15 (71.4%) subjects underwent a total of 26 cleft rhinoplasties that did not require grafting. In the definitive group, 18 (76%) subjects required cartilage grafting over 21 cleft rhinoplasties, whereas 7 (24%) subjects underwent a total of 9 cleft rhinoplasties where cartilage grafting was not required. The difference between the number of subjects requiring cartilage grafting in the intermediate versus the definitive group was statistically significant ( P = .007). Ear concha and nose were the most frequently used cartilage donor sites, with no observed complications. Conclusions: Cartilage grafting was significantly more common in the definitive rhinoplasty group. Intermediate cleft rhinoplasty during the 5- to 13-year age period was effective, with a low-risk profile. In our experience, ear concha and nose were the preferred cartilage donor sites, with effective results and an excellent safety profile.


Sign in / Sign up

Export Citation Format

Share Document